NICE recommends heart drug aficamten with simultaneous MHRA approval

The National Institute for Health and Care Excellence said that aficamten is likely to be as effective as mavacamten in treating obstructive hypertrophic cardiomyopathy, with “fewer monitoring scans to find the right dose”.…